Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TS-172
- Development stage
- Phase 3
- Lead developer
- Taisho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TS-172 is an orally administered small molecule drug being developed by Taisho Pharmaceutical for the treatment of hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood. The drug is currently in phase 3 clinical trials in Japan for this indication. While its precise mechanism of action has not been publicly defined, it is classified among hyperphosphatemia therapies and may act as a phosphate binder or through another pathway to reduce serum phosphate levels. As of now, there are no approved indications or known adverse events reported for TS-172[1][2][4].
- Other names
- TS 172TS172TS-172
Beyond the preview
Go deeper on TS-172.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TS-172.